Condition
Invasive Group A Beta-Haemolytic Streptococcal Disease
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
Trial Status
Unknown3
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06297122CompletedPrimary
Severe Group A Streptococcus Infections in Paris, France, 2018-2023
NCT06126263Unknown
Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections
NCT06058117UnknownPrimary
Paediatric European Group A Streptococcal United Study.
NCT03507101UnknownPrimary
Invasive Disease Caused by Group A Streptococcus (GAS) (DICAR)
Showing all 4 trials